Log in to your Inderes Free account to see all free content on this page.
SynAct Pharma
17.56 SEK
-1.68 %
Less than 1K followers
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-1.68 %
-2.34 %
-21.78 %
-22.30 %
-18.33 %
-11.94 %
-76.84 %
-75.34 %
+280.95 %
SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.
Read moreMarket cap
987.12M SEK
Turnover
1.95M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.5.
2026
Interim report Q1'26
11.6.
2026
General meeting '26
20.8.
2026
Interim report Q2'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting
SynAct Pharma publishes Annual Report 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio